FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer
News
Celsion‘s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer. This designation helps speed the approval of potential medicines ... Read more